Pyrukynd (Mitapivat)
Brand Names: Pyrukynd
Methodology & AI Transparency ⓘ
Pyrukynd (Mitapivat) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Mitapivat (cross-referenced at /meds/mitapivat) and registered by Agios Pharmaceuticals, Inc., Pyrukynd operates as a prescription brand-name pyruvate kinase activator therapy (RxNorm 2594479; NDC 71334-205, 71334-210).
- 2 Real-world patient consensus: Commercial Pyrukynd monograph (5 mg/1 Tablet, Film Coated) cross-indexed with generic Mitapivat for therapeutic equivalence review.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $29.38 cash mean against $77.86 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Pyrukynd (Mitapivat): arthralgia (5.5%), nausea (9.2%), headache (7.4%).
Ask our AI Specialists anything about Pyrukynd (Mitapivat)
Pyrukynd (Mitapivat) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Mitapivat (cross-referenced at /meds/mitapivat) and registered by Agios Pharmaceuticals, Inc., Pyrukynd operates as a prescription brand-name pyruvate kinase activator therapy (RxNorm 2594479; NDC 71334-205, 71334-210). Under 2026-06-30 FDA labeling for 5 mg/1 Tablet, Film Coated; Kit, 1 Indications and usage pyrukynd: is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK).
Bioactive Mitapivat within Pyrukynd governs pyruvate kinase activator target modulation involving CYP2B6/UGT1A1 clearance pathways. Commercialized across 5 mg/1 Tablet, Film Coated; Kit (registered by Agios Pharmaceuticals, Inc., SPL 2026-06-30), Pyrukynd combines branded dosage-form consistency (NDC 71334-205, 71334-210) with transparent cash-pay comparisons spanning $29.38 to $77.86.
With Steady-state plasma equilibrium reached over 6–11 hour t½ intervals for Pyrukynd (Mitapivat) residence kinetics and Approximately 61% to 73% enteral uptake across labeled Pyrukynd (Mitapivat) strengths bioavailability, Pyrukynd (Mitapivat) undergoes phase i cyp2b6, ugt1a1 hepatic clearance and subsequent renal metabolite filtration and establishes therapeutic activity over maximum serum exposure occurs 2–4 hours after pyrukynd (mitapivat) dosing.
Standard adult regimens span 5 mg/1 Tablet, Film Coated, Kit, 20 mg/1 Tablet, Film Coated, 50 mg/1 Tablet, Film Coated. Prescribers screen specifically against previous anaphylactoid or exfoliative reaction attributed to pyrukynd (mitapivat); clinical scenarios where pyruvate kinase activator exposure from pyrukynd (mitapivat) poses unacceptable risk, while community micro-logs most frequently note nausea (9.2% of reports), headache (7.4% of reports), dizziness (6.3% of reports).
Systemic bioavailability and half-life of Pyrukynd (Mitapivat) respond to strong CYP2B6 enzymatic inhibition or induction.
Verify medication reconciliation lists so Pyrukynd (Mitapivat) is not inadvertently duplicated with another pyruvate kinase activator.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Pyrukynd (Mitapivat)
- Clinical scenarios where pyruvate kinase activator exposure from Pyrukynd (Mitapivat) poses unacceptable risk
Logged Side-Effect Incidence (22 Reports)
Pyrukynd (Mitapivat) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pyrukynd (Mitapivat))
Human clinical trial evidence for Pyrukynd (Mitapivat) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Pyrukynd (Mitapivat) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2900/unit (~$8.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $77.86 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $29.38 / mo | View logs ↓ |
Pyrukynd (Mitapivat) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pyrukynd (Mitapivat) RxNorm Concept ID | 2594479 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $77.86 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $29.38 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pyrukynd (Mitapivat) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Pyrukynd (Mitapivat) (pyruvate kinase activator) monograph synthesizing RxNorm 2594479, openFDA FAERS signals, and $29.38–$77.86 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pyrukynd (Mitapivat) community threads and patient logs by age, biological sex, dosage, and treatment duration.